MX372739B - Metodos y composiciones para inhibir cnksr1. - Google Patents

Metodos y composiciones para inhibir cnksr1.

Info

Publication number
MX372739B
MX372739B MX2015007608A MX2015007608A MX372739B MX 372739 B MX372739 B MX 372739B MX 2015007608 A MX2015007608 A MX 2015007608A MX 2015007608 A MX2015007608 A MX 2015007608A MX 372739 B MX372739 B MX 372739B
Authority
MX
Mexico
Prior art keywords
methods
compositions
cnksr1
inhibiting
inhibiting cnksr1
Prior art date
Application number
MX2015007608A
Other languages
English (en)
Other versions
MX2015007608A (es
Inventor
Nathan T Ihle
Martin Indarte
D Lynn Kirkpatrick
Original Assignee
Phusis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phusis Therapeutics Inc filed Critical Phusis Therapeutics Inc
Publication of MX2015007608A publication Critical patent/MX2015007608A/es
Publication of MX372739B publication Critical patent/MX372739B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Las modalidades incluyen composiciones y métodos para inhibir CNKSR1 y métodos para identificar los inhibidores de CNKSR1.
MX2015007608A 2012-12-14 2013-12-16 Metodos y composiciones para inhibir cnksr1. MX372739B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737658P 2012-12-14 2012-12-14
PCT/US2013/075505 WO2014093988A2 (en) 2012-12-14 2013-12-16 Methods and compositions for inhibiting cnksr1

Publications (2)

Publication Number Publication Date
MX2015007608A MX2015007608A (es) 2016-04-13
MX372739B true MX372739B (es) 2020-05-06

Family

ID=50935099

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019015648A MX393754B (es) 2012-12-14 2013-12-16 Metodos y composiciones para inhibir cnksr1
MX2015007608A MX372739B (es) 2012-12-14 2013-12-16 Metodos y composiciones para inhibir cnksr1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019015648A MX393754B (es) 2012-12-14 2013-12-16 Metodos y composiciones para inhibir cnksr1

Country Status (7)

Country Link
US (1) US9340532B2 (es)
EP (1) EP2931280B1 (es)
JP (1) JP6357292B2 (es)
AU (1) AU2013358876B2 (es)
CA (1) CA2895162C (es)
MX (2) MX393754B (es)
WO (1) WO2014093988A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2931280B1 (en) 2012-12-14 2018-02-14 Phusis Therapeutics Inc. Methods and compositions for inhibiting cnksr1
WO2016172191A1 (en) * 2015-04-20 2016-10-27 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting cnksr1
US20190367457A1 (en) 2016-12-30 2019-12-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
CN110698411B (zh) * 2018-07-09 2023-05-09 四川大学 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途
WO2022026465A1 (en) * 2020-07-28 2022-02-03 Mirati Therapeutics, Inc. Sos1 inhibitors
WO2022187804A1 (en) * 2021-03-02 2022-09-09 Icahn School Of Medicine At Mount Sinai Benzoxazolone inhibitors of inflammasomes
WO2024192873A1 (zh) * 2023-03-20 2024-09-26 杭州天玑济世生物科技有限公司 一类具有萘胺结构的小分子化合物的用途
CN116444477B (zh) * 2023-04-04 2026-01-02 宁波九胜创新医药科技有限公司 一种溴代胡椒环羧酸的制备方法及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA775563A (en) 1968-01-09 Frank W. Horner Limited Hypoglycemic thiadiazoles
GB828963A (en) 1956-08-03 1960-02-24 Rhone Poulenc Sa Pharmaceutical compositions containing 2-p-aminobenzenesulphonamido-5-t-butyl-1, 3, 4-thiadiazole
US3821222A (en) 1971-11-22 1974-06-28 Chevron Res Hydrocarbyl sulfenylmercapto pyrimidines
US4017489A (en) 1975-07-10 1977-04-12 The Goodyear Tire & Rubber Company Process of preparing unsymmetrical disulfides
DE2556011A1 (de) 1975-12-12 1977-06-23 Merck Patent Gmbh Disulfide
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
GB2152497B (en) 1983-11-28 1987-08-05 Otsuka Kagaku Kk Process for the preparation of azetidinone derivatives
FR2573077B1 (fr) 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4990523A (en) 1989-06-19 1991-02-05 A. H. Robins Company, Incorporated Treatment of chronic inflammatory joint disease with arylsulfonamides
GB9507415D0 (en) * 1994-06-08 1995-05-31 Zylepsis Ltd Production and uses of caffeic acid and derivatives thereof
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
WO2002083064A2 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
CA2456985A1 (en) * 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003084473A2 (en) 2002-04-08 2003-10-16 Merck & Co., Inc. Method of treating cancer
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
EP1644390B1 (en) 2003-06-24 2011-04-20 Isis Innovation Limited Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
CA2531418A1 (en) 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
EP1751225B1 (en) 2004-03-19 2009-08-05 The Tapemark Company Thermoplastic films and methods for making
US20050288347A1 (en) 2004-03-26 2005-12-29 Hodge Carl N Certain triazole-based compounds, compositions, and uses thereof
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
RU2008113208A (ru) 2005-10-06 2009-10-10 Санофи-Авентис (Fr) Циклические n-[1, 3, 4]-тиадиазол-2-илбензолсульфонамиды, способ их получения и их применение в качестве лекарственных средств
WO2007106391A1 (en) 2006-03-10 2007-09-20 Lymphosign Inc. Compounds for modulating cell proliferation, compositions and methods related thereto
KR101499783B1 (ko) 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US20080153789A1 (en) 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
MX2010011258A (es) 2008-04-14 2011-06-20 Univ Texas Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
WO2010085968A1 (en) * 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
EP2417123A2 (en) * 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
US20120189670A1 (en) * 2009-09-14 2012-07-26 Kirkpatrick D Lynn Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
AU2012240030A1 (en) * 2011-04-05 2013-10-24 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of TRA kinase
EP2931280B1 (en) 2012-12-14 2018-02-14 Phusis Therapeutics Inc. Methods and compositions for inhibiting cnksr1

Also Published As

Publication number Publication date
JP2016508969A (ja) 2016-03-24
JP6357292B2 (ja) 2018-07-11
WO2014093988A2 (en) 2014-06-19
EP2931280A2 (en) 2015-10-21
MX393754B (es) 2025-03-24
CA2895162A1 (en) 2014-06-19
CA2895162C (en) 2021-03-09
US9340532B2 (en) 2016-05-17
WO2014093988A3 (en) 2014-08-07
US20150307482A1 (en) 2015-10-29
MX2015007608A (es) 2016-04-13
EP2931280B1 (en) 2018-02-14
EP2931280A4 (en) 2016-06-01
AU2013358876A1 (en) 2014-06-19
AU2013358876B2 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
BR112013025006A2 (pt) composições e métodos para inibição de expressão do gene tmprss6
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CL2018003282A1 (es) Métodos y composiciones para el tratamiento de cánceres resistentes a los inhibidores de la vía no erk mapk
CO7091177A2 (es) Inhibidores de la beta-secretasa
BR112013028281A2 (pt) compostos e composições para inibição de nampt
UY33930A (es) Inhibidores novedosos de quinasas
UY33925A (es) Inhibidores tricíclicos de quinasas
CO7020912A2 (es) Inhibidores de bromodominios
CR20140024A (es) Compuestos inhibidores de metaloenzimas
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
HRP20181199T1 (hr) Laktamski derivati, korisni kao inhibitori mutantnog idh1
CR20150462A (es) Inhibidores de erk y sus usos
PT2773748T (pt) Neurónios dopaminérgicos (da) do mesencéfalo para enxerto
LT2841428T (lt) Dnr-pk inhibitoriai
BR112015023310A2 (pt) composições, métodos e kits para redução de níveis lipídicos
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
HUE037312T2 (hu) Hiszton demetiláz inhibitorok
MX372739B (es) Metodos y composiciones para inhibir cnksr1.
HUE058085T2 (hu) Glükozilceramid-szintáz inhibitorai
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
BR112015003294A2 (pt) caldeira de armazenamento
CR20150133A (es) Amino-quinolinas como inhibidores de cinasa

Legal Events

Date Code Title Description
FG Grant or registration